Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00510068 · OUTCOME

Plasma Angiogenesis Marker: Soluble Vascular Endothelial Growth Factor Receptor 1 (sVEGFR1)

Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors · Source last updated 2015-07-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
pg/mL
Interval / dispersion
Standard Deviation
Time frame
Baseline, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1

What was measured

This biomarker is related to angiogenesis pathway, was analyzed to determine the effects of everolimus on plasma antiangiogenic molecules.

Analysis population: The Full Analysis Set (FAS) consists of all patients who were randomized.

Groups in this outcome

Everolimus 10 mg/Day

Participants received 10 mg per day of everolimus plus best supportive care. Patients received their first dose of everolimus at Visit 2 (Cycle 1 Day 1).

Placebo

Participants received matching placebo to everolimus daily plus best supportive care. Patients received their first dose of matching placebo at Visit 2 (Cycle 1 Day 1).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Everolimus 10 mg/Day207
Placebo203

Reported measurements

Baseline (n:198, 195)
Values in pg/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Everolimus 10 mg/Day264.18272.190Not reportedNot reportedNot reported
Placebo256.69187.866Not reportedNot reportedNot reported
Cycle 2 Day 1 (n: 185, 184)
Values in pg/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Everolimus 10 mg/Day307.46808.316Not reportedNot reportedNot reported
Placebo299.03541.933Not reportedNot reportedNot reported
Cycle 3 Day 1 (n: 185, 174)
Values in pg/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Everolimus 10 mg/Day263.81187.329Not reportedNot reportedNot reported
Placebo253.37250.841Not reportedNot reportedNot reported
Cycle 4 Day 1 (n: 171, 159)
Values in pg/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Everolimus 10 mg/Day258.03223.980Not reportedNot reportedNot reported
Placebo242.17163.561Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        272.190
        value
        264.18
      2. group Id
        OG001
        spread
        187.866
        value
        256.69
    title
    Baseline (n:198, 195)
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        808.316
        value
        307.46
      2. group Id
        OG001
        spread
        541.933
        value
        299.03
    title
    Cycle 2 Day 1 (n: 185, 184)
  3. categories
    1. measurements
      1. group Id
        OG000
        spread
        187.329
        value
        263.81
      2. group Id
        OG001
        spread
        250.841
        value
        253.37
    title
    Cycle 3 Day 1 (n: 185, 174)
  4. categories
    1. measurements
      1. group Id
        OG000
        spread
        223.980
        value
        258.03
      2. group Id
        OG001
        spread
        163.561
        value
        242.17
    title
    Cycle 4 Day 1 (n: 171, 159)
denoms
  1. counts
    1. group Id
      OG000
      value
      207
    2. group Id
      OG001
      value
      203
    units
    Participants
description
This biomarker is related to angiogenesis pathway, was analyzed to determine the effects of everolimus on plasma antiangiogenic molecules.
dispersion Type
Standard Deviation
groups
  1. description
    Participants received 10 mg per day of everolimus plus best supportive care. Patients received their first dose of everolimus at Visit 2 (Cycle 1 Day 1).
    id
    OG000
    title
    Everolimus 10 mg/Day
  2. description
    Participants received matching placebo to everolimus daily plus best supportive care. Patients received their first dose of matching placebo at Visit 2 (Cycle 1 Day 1).
    id
    OG001
    title
    Placebo
param Type
MEAN
population Description
The Full Analysis Set (FAS) consists of all patients who were randomized.
reporting Status
POSTED
time Frame
Baseline, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1
title
Plasma Angiogenesis Marker: Soluble Vascular Endothelial Growth Factor Receptor 1 (sVEGFR1)
type
SECONDARY
unit Of Measure
pg/mL

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice